Introduction Thymic stromal lymphopoietin (TSLP), an epithelial cytokine (alarmin), is a
central regulator of the immune response to inhaled environmental insults such as …

The alarmin cytokines thymic stromal lymphopoietin (TSLP), interleukin (IL)‐33, and IL‐25
are epithelial cell‐derived mediators that contribute to the pathobiology and …

Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …

Sepsis, a prevalent critical condition in clinics, continues to be the leading cause of death
from infections and a global healthcare issue. Among the organs susceptible to the harmful …

The field of asthma has undergone a dramatic change in recent years. Advances in our
understanding of type 2 airway inflammation have driven the discovery of monoclonal …

Type 2 immunity evolved to combat helminth infections by orchestrating a combined
protective response of innate and adaptive immune cells and promotion of parasitic worm …

Recent developments in therapeutic strategies have provided alternatives to corticosteroids
as the cornerstone treatment for managing airway inflammation in asthma. The past two …

Biologics, including omalizumab, mepolizumab, benralizumab, and dupilumab, targeting
downstream IgE, cytokines IL-5, and IL-4/13, respectively, have shown promising effects in …

Background IL-25 can function as an early signal for the respiratory type 2 response
characteristic of allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). In …

Thymic stromal lymphopoietin (TSLP) is an innate cytokine, belonging to the group of
alarmins, which plays a key pathogenic role in asthma by acting as an upstream activator of …